Â鶹Çø

Kyle Greenway, MD

Dr. Kyle Greenway - PsychiatristKyle Greenway, MD MSc FRCPC, is an Assistant Professor in Psychiatry at Â鶹Çø, attending psychiatrist at the Jewish General Hospital, and investigator at the Lady Davis Institute. He conducts clinical, naturalistic, and fundamental research on novel psychiatric interventions, particularly psychedelic-assisted psychotherapies for refractory depressive disorders. He leads the Ketamine-Assisted Therapy service at the Jewish General Hospital, one of only a handful of clinics in the world to offer a psychedelic therapy for severe depression in a public payer system. His work explores the impacts of extra-pharmacological factors on psychedelic and conventional psychiatric treatments, including how treatment protocols can be tailored to individuals based on their unique life experiences and cultures. Before joining Â鶹Çø, Dr. Greenway completed postdoctoral studies at the world-leading Imperial College Psychedelic Research Centre, as well as the Â鶹Çø Clinical Investigator Program.

kyle.greenway [at] mail.mcgill.ca (Email)Ìý´¥


Selected Articles

Greenway, K. T., Garel, N., Dinh-Williams, L. A. L., Beaulieu, S., Turecki, G., Rej, S., & Richard-Devantoy, S. (2024). Music as an Intervention to Improve the Hemodynamic Response of Ketamine in Depression: A Randomized Clinical Trial. JAMA Network Open, 7(2), e2354719-e2354719.

Garel, N., Drury, J., Lévesque, J. T., Goyette, N., Lehmann, A., Looper, K., ... & Greenway, K. T. (2023). The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression. Frontiers in Psychiatry, 14.

Garel, N., Lévesque, J. T., Sandra, D. A., Lessard-Wajcer, J., Solomonova, E., Lifshitz, M., ... & Greenway, K. T. (2023). Imprinting: expanding the extra-pharmacological model of psychedelic drug action to incorporate delayed influences of sets and settings. Frontiers in Human Neuroscience, 17.

Back to top